Myeloid Leukemia
Articles tagged with Myeloid Leukemia
Are we seeing changes in the rates of secondary blood-related cancers that develop due to chemotherapy or radiation?
A study from Japan has revealed a gradual increase in tAML rates, especially after breast cancer treatment. The study analyzed data from the Osaka Cancer Registry and found that the annual incidence of tAML increased from 0.13 to 0.36 per 100,000 population between 1990 and 2020.
Leukemia study restores silenced gene in mice. Could it point to new treatments for humans?
Researchers created a CRISPR-based tool to pinpoint genes the cancer turns off, restoring a key cancer-fighting gene in leukemia. The study found that blocking KDM4 enzymes can regain expression of the tumor-suppressor gene ZBTB7A, reducing leukemia burden while leaving normal blood formation largely unaffected.
The University of Colorado Anschutz Gates Institute achieves first-in-U.S. FDA clearance for campus-built CAR T-cell therapy
The University of Colorado Anschutz Gates Institute has achieved first-in-U.S. FDA clearance for a novel CAR T-cell therapy targeting aggressive leukemia cells, representing a potential new treatment approach for patients with hard-to-treat disease. The therapy will be evaluated in a Phase 1 clinical trial starting this summer.
New analytical method reveals how drug combinations act in leukemia – study opens the door to precision designed combinatorial therapies
A new study introduces CoPISA, a high-throughput proteomics workflow that uncovers how drug combinations reshape the soluble proteome. The research team applied CoPISA to two AML drug combinations, revealing conjunctional targeting and vulnerabilities in critical proteins.
Agent Orange linked to aggressive bone marrow cancer in Vietnam veterans
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
Alliance trial aims to improve outcomes for chronic lymphocytic leukemia
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
RELAX study from Dresden: Innovative combination therapy shows promising efficacy in aggressive leukemia
Researchers from Dresden University Medicine developed a new treatment approach for relapsed acute myeloid leukemia (AML), combining standard therapy with the BCL2 inhibitor venetoclax. The innovative combination therapy has shown promising efficacy, increasing remission rates to 75% and improving patients' chances of recovery.
Upcoming Alliance webinar highlights latest cancer treatment advances
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
OHSU researchers find breast cancer drug boosts leukemia treatment
Researchers at OHSU discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome treatment resistance by pairing venetoclax, a standard AML drug, with palbociclib, a cell-cycle inhibitor approved for breast cancer. The study found that this combination produced significantly stronger and m...
Black patients diagnosed with aggressive leukemia experience worse outcomes, but differences not linked to key genetic changes
A new study by University of Maryland researchers found that Black patients with aggressive leukemia have lower survival rates and are more likely to die from the disease compared to white patients. The disparity is attributed to younger age at diagnosis rather than genetic differences, according to Dr. Shella Saint Fleur-Lominy.
ASH 2025: Study connects Agent Orange exposure to earlier and more severe cases of myelodysplastic syndrome
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy
The azacitidine-venetoclax combination significantly improves event-free survival and overall response rates compared to intensive chemotherapy. Patients in the aza-ven arm also experience lower symptom burdens, reduced depression, and improved quality of life.
Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients
Black patients with acute myeloid leukemia are diagnosed at younger ages and have worse outcomes compared to white patients, according to a study analyzing data from 10 clinical trials over 34 years. The study found that Black patients had a higher risk of dying from AML and any cause, even when treated with similar mutations.
Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia
Researchers found that measurable residual disease (MRD) is strongly associated with long-term outcomes in AML patients, providing a reliable indicator of treatment response. MRD testing may help refine how physicians assess treatment efficacy and personalize post-remission care.
Sylvester researchers lead major treatment overhauls for acute myeloid leukemia
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Much-needed new drug approved for deadliest blood cancer
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
ASH 2025 posters preview from Sylvester Comprehensive Cancer Center
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
Researchers discover a safe new target against Acute Myeloid Leukaemia
Researchers have identified a new histone variant, macroH2A1.1, as a potential therapeutic target for treating Acute Myeloid Leukaemia. The study found that targeting this variant is safe for patients and may lead to new treatment options.
New drug combinations pave the way for personalised leukaemia therapies
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Targeted immunotherapy combination offers hope to older adults with leukemia
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
Combination therapy could expand treatment options for AML patients, extend survival
A new study reveals that combining proteasome inhibitors with Lys05 can effectively kill AML cells by disabling backup survival pathways. This approach has shown promise in preclinical models and could lead to improved treatment options for a wider range of AML patients.
Alliance Global study challenges age-based treatment decisions in leukemia
A recent study published in Leukemia found that age-based classifications in acute myeloid leukemia (AML) treatment may be outdated. The research analyzed data from 2,823 adult AML patients, revealing nuanced age-related trends in genetic mutations and survival outcomes.
City of Hope Research Spotlight, September 2025
Researchers at City of Hope have identified a potential strategy to overcome treatment resistance in acute myeloid leukemia and uncovered racial disparities in triple-negative breast cancer. By targeting the ALKBH1 protein, which enhances energy production in cancer cells, scientists found that blocking this protein could make CAR T th...
New mechanism revealed: How leukemia cells trick the immune system
A team at Lund University has discovered a surface protein, SLAMF6, that helps leukemia cells evade the immune system. The researchers developed an antibody to block this mechanism, restoring the immune system's ability to kill cancer cells in laboratory trials and mice.
A natural compound could help fight aggressive leukemia and amplify the effect of chemotherapy drugs
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
Study uncovers molecular “switch” behind chemoresistance in blood cancer
Researchers have identified a previously unknown molecular mechanism behind chemoresistance in acute myeloid leukemia (AML), a type of blood cancer. The study found that a protein called RUNX1C plays a key role in this process, and blocking its activity with RNA-targeting tools can improve chemotherapy's effectiveness.
Integrative scATAC-seq and mtDNA mutation analysis reveals disease-driven regulatory aberrations in AML
The study identified significant alterations in chromatin accessibility of cis-regulatory elements associated with AML differentiation, linked to mutations in the WT1 transcription factor gene. These changes led to reduced chromatin accessibility and downregulation of target genes, promoting AML proliferation.
Immunotherapy for leukemia may affect the bone marrow environment, cancer researchers find
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
Study: olutasidenib is highly effective in certain patients with myelodysplastic syndrome
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
Study shows DNA regulatory switch prompts stem cells to give rise to blood
A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.
MD Anderson Research Highlights for July 16, 2025
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
Fighting leukemia by breaking a hidden cell loop
Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.
New model to find treatments for an aggressive blood cancer
Researchers created a powerful cell culture model using induced pluripotent stem cells from a patient with MDS, confirming that the CEBPA mutation drives disease progression. The model could lead to new ways to treat and diagnose MDS and avoid more serious conditions.
MD Anderson Research Highlights for June 26, 2025
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
Understanding how a key protein helps aggressive blood cancer grow, paving the way for targeted therapies
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
Targeting fusion protein’s role in childhood leukemia produces striking results
Researchers at St. Jude Children's Research Hospital have identified a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML) fueled by NUP98 fusions. Targeting the complex alone or in combination with another anticancer drug significantly increased survival in AML model systems.
A downside of taurine: it drives leukemia growth
Scientists discovered that taurine drives leukemia growth by promoting glycolysis and is produced by normal cells in the bone marrow microenvironment. Researchers identified taurine transporter expression as essential for leukemia cell growth, leading to potential new therapeutic targets.
MD Anderson Research Highlights for May 8, 2025
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
ZW27941: A novel therapeutic strategy for acute myeloid leukemia
A new study published in Genes & Diseases journal introduces a novel therapeutic approach for acute myeloid leukemia (AML) using the METTL3 degrader ZW27941. The research team found that ZW27941 exhibited potent anti-leukemic activity and synergistic effects with existing AML therapies.
How do neighborhoods impact children's chances of surviving leukemia?
A study by UC San Francisco found that children with ALL living in mixed middle- and low-income neighborhoods have a 30-40% higher risk of death. In contrast, AML hospital treatments are shorter, and outpatient visits fewer, reducing challenges for underserved patients.
Long-term survival rates of some Acute Myeloid Leukaemia patients could double with sensitive bone marrow test
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
Single-cell RNA sequencing provides comprehensive map of acute myeloid leukemia cell states
A new gene expression atlas from single-cell RNA sequencing data reveals normal hematopoietic cell differentiation patterns and identifies novel AML cell states. Researchers cataloged multiple ways aberrant differentiation leads to AML, with potential biomarkers and drug targets emerging.
Off-the-shelf CAR natural killer cell therapy with logic gates elicits complete remissions in relapsed or refractory blood cancers
A new CAR NK cell therapy has shown promising results in treating relapsed or refractory blood cancers, particularly AML. The therapy, SENTI-202, employs logic gating to improve specificity and reduce toxicity, and has been associated with complete remissions in seven of nine patients.
A new druggable cancer target: RNA-binding proteins on the cell surface
Researchers have discovered a new druggable cancer target, NPM1, which is expressed on the surface of malignant AML cells. Monoclonal antibodies targeting NPM1 showed robust anti-tumor activity in multiple in vivo models of AML, with no apparent toxicity to non-cancerous blood cells and stem cells.
MD Anderson Research Highlights for April 17, 2025
Researchers at MD Anderson Cancer Center have discovered that adding copper-loaded agents to radiotherapy can overcome radioresistance in preclinical models of thoracic cancer. A novel blood-based biomarker, OSMR, has also been identified in patients with acute myeloid leukemia (AML), which shows prognostic potential and can help ident...
Drug-delivering aptamers target leukemia stem cells for one-two knockout punch
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients
Researchers at UT Health San Antonio have identified a novel drug target for acute myeloid leukemia, which showed significant delays in disease progression and improved survival rates. The protein paraspeckle component 1 (PSPC1) plays a crucial role in the disease, and targeting it may offer new treatment options for AML patients.
Single protein mimics retinoic acid therapy to help leukemia cells mature
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
Digital PCR can reliably determine if chronic myeloid leukemia patients in remission can successfully discontinue drug treatment
Researchers found that digital PCR for BCR::ABL1 is more sensitive and accurate than conventional real-time quantitative PCR to detect ultralow levels of residual leukemic disease. The technology enabled the detection of stable deep molecular remission in 97% of patients, allowing for safe discontinuation of treatment.
Small device, big impact: Improving safety of life-saving treatments for children with leukemia
Researchers developed a microfluidic device to alleviate limitations of conventional blood-filtering machines used in treating hyperleukocytosis in children. The new device separates blood cells by size without platelet loss or adverse effects, enabling safe leukapheresis procedures.
MD Anderson Research Highlights for March 12, 2025
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
New combination treatment strategy dramatically increases cell death in leukemia
Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.
Applications of molecular genetic testing in hematopoietic and lymphocytic neoplasms
Key molecular applications in diagnosing and managing hematopoietic and lymphocytic neoplasms include comprehensive mutational profiling, aiding accurate diagnosis and prognostication. The use of targeted therapies against specific genetic abnormalities further refines treatment selection.
MD Anderson Research Highlights for February 26, 2025
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
New technique reveals how the same mutations give rise to very different types of leukaemia
A new study has identified two cell types with distinct biological properties that respond differently to treatment after acquiring the same mutation. Understanding these differences is crucial for developing personalized therapies and preventing aggressive forms of cancer.
Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital invest $1.8 million in childhood cancer research
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
Rare case of donor cell-derived blood cancer discovered nine years after stem cell transplant
A new case report reveals a rare and aggressive form of leukemia developing from donor cells nine years after a stem cell transplant. The disease, driven by genetic mutations in key genes, progresses despite intensive treatment and ultimately proves fatal.
Study unveils key immune cells found to boost cancer treatment success in acute myeloid leukemia
Researchers have identified a unique population of T cells that play a critical role in successful treatment of relapsed acute myeloid leukemia. A healthier immune environment in the bone marrow supports these cells and their cancer-fighting abilities.
EMBARGOED: Dana-Farber investigators pinpoint keys to cell therapy response for leukemia
Dana-Farber investigators pinpoint the importance of cell type and tumor microenvironment in determining DLI response. Patients who responded to DLI had distinct cellular populations in their bone marrow, which may indicate 'hot' or 'cold' forms of AML.